<DOC>
	<DOCNO>NCT00171379</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy equimolar conversion MMF enteric-coated mycophenolate sodium , renal transplant patient receive cyclosporine .</brief_summary>
	<brief_title>Clinical Study Evaluate Tolerability , Safety Efficacy Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil ( MMF ) Patients With Renal Transplant</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>First second ( single double ) decease live donor kidney transplant receive least six month previously ; Immunosuppressive therapy cyclosporin mycophenolate mofetil ( MMF ) ; Receiving MMF dose &lt; 2/g/day adverse event and/or alter laboratory test result attribute MMF â€¢ Subjects expect discontinue cyclosporin therapy ; Patients thrombocytopenia ( &lt; 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 and/or leukopenia ( &lt; 2,500/mm3 ) , anemia ( hemoglobin &lt; 6 g/dl ) baseline ; Patients experience acute rejection previous two month , inadequate ( creatininemia &gt; 2.5 mg/dL ) worsen renal function previous two month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Kidney transplantation ; acute rejection ; gastrointestinal adverse event ; quality life ; mycophenolate sodium .</keyword>
</DOC>